United States HIV Drugs Market Report and Forecast 2025-2034

United States HIV Drugs Market Outlook

The United States HIV drugs market is estimated to expand at a CAGR of 4.3% in the forecast period of 2025-2034.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

United States and HIV Drugs Market Growth

United States and many other countries in other regions witness large number of cases of HIV infection. Unites States noted a major spike in the number of new cases according to most recent data, with the southern states taking the highest numbers among all. It was followed by the West, North-East and Midwest parts of the United States. The demand for drugs for the same will be greater to cater to new and existing cases collectively. More testing centers will also help in early detection of HIV positives and, accordingly, people can start with prescribed medicines to protect themselves from very serious harm. Innovation will also help in rising in the market, like creating more multidimensional medicines such that the burden of consuming different pills is minimized, or lesser dosage is required in a particular time.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

United States HIV Drugs Market: Market Segmentation

HIV, human immunodeficiency virus, infection is a condition which attacks and weakens the immune system of people. There are three stages of the infection, acute, chronic and the final and most severe acquired immunodeficiency disease (AIDS). HIV medicines can help in viral suppression, by decreasing the viral load which can protect the immune system and prevent transmission too. Some medicines do this by blocking or altering the enzymes that help the virus multiply. Some refrain the virus from decreasing the CD4 cell count, which fight the pathogens or infections.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on the types of HIV drugs, the market is divided into:

• Antiretroviral Therapy (ART)
• Pre-Exposure Prophylaxis (Prep)

The different classes of HIV drugs are:

• Nucleoside Reverse Transcriptase Inhibitors
• Multi-Class Combination Products
• Protease Inhibitors
• HIV Integrase Strand Transfer Inhibitors
• Non-Nucleoside Reverse Transcriptase Inhibitors
• Entry Inhibitors — CCR5 Co-Receptor Antagonist
• Fusion Inhibitors
• Combination
• Others

The route of administration of the drugs in the include:

• Oral
• Topical

Different distribution channels are divided into:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Rising Demand leading the Market Growth

The rising density of HIV-infected people in the population has helped in the production and implementation of HIV drugs. The market is affected by rising government initiatives and campaigns to raise public consciousness about the causes, symptoms, and treatments of HIV. Furthermore, the launch of generic drugs, which are less expensive and chemically similar to branded drugs, is another factor adding to the demand for HIV drugs. Several international organizations provide funds to research institutes for R&D activities in order to develop innovative, accessible, secure, and reliable medicines for successful therapeutic solutions. The aforementioned factors are expected to drive up demand for HIV drugs over the forecast period.

Key Industry Players in the HIV Drugs Market of United States include

The report presents a detailed analysis of the following key players in the HIV drugs market of United States, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Gilead Sciences, Inc
• Janssen Global Services, LLC (Johnson & Johnson
• ViiV Healthcare group of companies (GSK)
• Merck Sharp & Dohme Corp (Merck & Co)
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report

United States HIV Drugs Market Report Snapshots

United States HIV Drugs Market Size

United States HIV Drugs Market Growth

United States HIV Drugs Companies